Share Price and Basic Stock Data
Last Updated: December 4, 2025, 1:17 am
| PEG Ratio | -3.34 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lasa Supergenerics Ltd operates in the specialty chemicals sector, focusing on a niche market. The company reported a market capitalization of ₹49.4 Cr and a current share price of ₹9.94. Revenue trends indicate a fluctuating sales performance, with total sales reporting ₹130 Cr for FY 2023, a decline from ₹137 Cr in FY 2022. Quarterly sales peaked at ₹35 Cr in March 2023 but subsequently fell to ₹24 Cr in September 2023. The trailing twelve-month (TTM) sales stood at ₹132 Cr, indicating some recovery potential. In the most recent quarters, sales have shown volatility, with ₹31 Cr in June 2023 and ₹24 Cr in September 2023. The company aims to stabilize its sales by improving its product mix and increasing market penetration. However, the overall revenue trajectory remains a concern, especially with net profit declining to ₹-39 Cr in FY 2023, reflecting ongoing operational challenges.
Profitability and Efficiency Metrics
Lasa Supergenerics’ profitability metrics reveal ongoing challenges, with an operating profit margin (OPM) recorded at -5% for FY 2023, improving slightly to 4% in FY 2024. The company has struggled with negative net profits, which stood at ₹-39 Cr for FY 2023, further declining to ₹-15 Cr in FY 2024. The interest coverage ratio (ICR) improved to 4.19x, indicating better ability to service debt, yet the return on equity (ROE) remained low at 1.01%. The cash conversion cycle (CCC) was reported at 53 days, suggesting inefficiencies in working capital management. The company has recorded significant fluctuations in earnings per share (EPS), with a TTM EPS of ₹-6.61. This inconsistent profitability raises concerns about the sustainability of operations and the potential for future growth within the competitive landscape of the specialty chemicals sector.
Balance Sheet Strength and Financial Ratios
Lasa Supergenerics’ balance sheet reflects a cautious financial position, with total borrowings reported at ₹7 Cr against reserves of ₹6 Cr. The current ratio stood at 1.90, indicating a comfortable liquidity position, while the quick ratio was lower at 0.46, suggesting potential short-term liquidity issues. The company’s debt-to-equity ratio was reported at 0.03, showing minimal leverage, which is a strength in volatile markets. However, the book value per share decreased from ₹36.54 in FY 2022 to ₹16.71 in FY 2025, highlighting erosion in shareholder value. The price-to-book value ratio stood at 1.01x, suggesting the stock may be fairly valued relative to its net assets. Overall, while the balance sheet reflects some stability, the declining asset values and modest reserve levels call for a review of operational efficiency and asset management strategies.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lasa Supergenerics indicates a significant promoter holding of 53.65%, which has remained stable since March 2023. The public shareholding stands at 46.35%, with foreign institutional investors (FIIs) holding a negligible 0.00%, reflecting limited interest from external institutional investors. The total number of shareholders has shown some fluctuations, with 28,656 reported as of September 2025. The stable promoter ownership may instill some confidence among retail investors, yet the absence of institutional backing raises questions about the company’s attractiveness to larger investors. Furthermore, the retention of public interest is crucial, especially given the company’s recent financial struggles. While the promoter’s commitment is a positive signal, the overall lack of institutional investment may reflect broader market skepticism regarding the company’s growth prospects.
Outlook, Risks, and Final Insight
Looking ahead, Lasa Supergenerics faces both opportunities and challenges. Strengths include a solid promoter backing and a low debt-to-equity ratio, which may offer some resilience in uncertain market conditions. However, significant risks persist, including the ongoing volatility in sales and profitability, coupled with a declining trend in net profits. Operational efficiencies need to be prioritized to improve margins and overall financial health. The company should focus on enhancing its product offerings and exploring new markets to drive revenue growth. Conditional scenarios could involve a turnaround in profitability if operational efficiencies are improved, while continued declines in sales and profits could lead to further investor skepticism and potential liquidity challenges. In conclusion, while the company has foundational strengths, it must navigate its operational challenges effectively to regain investor confidence and achieve sustainable growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lasa Supergenerics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 400 Cr. | 43.5 | 86.7/42.2 | 24.9 | 20.5 | 0.92 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 33.3 Cr. | 67.8 | 103/56.0 | 15.9 | 89.6 | 1.47 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 45.7 Cr. | 672 | 988/600 | 21.0 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,397 Cr. | 74.9 | 111/74.5 | 22.5 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 680 Cr. | 273 | 453/241 | 24.4 | 93.8 | 0.92 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,715.00 Cr | 715.03 | 62.40 | 183.02 | 0.43% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 34 | 32 | 35 | 31 | 24 | 27 | 23 | 31 | 39 | 33 | 39 | 20 |
| Expenses | 37 | 34 | 34 | 31 | 27 | 23 | 26 | 27 | 29 | 39 | 33 | 36 | 21 |
| Operating Profit | -8 | -0 | -2 | 4 | 4 | 1 | 1 | -4 | 2 | 1 | 0 | 3 | -0 |
| OPM % | -28% | -1% | -8% | 12% | 13% | 4% | 4% | -17% | 6% | 2% | 1% | 9% | -2% |
| Other Income | 0 | -2 | 1 | -19 | 0 | 0 | 0 | -9 | 0 | 2 | 9 | -22 | -20 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 2 |
| Profit before tax | -11 | -7 | -5 | -19 | 1 | -2 | -2 | -16 | -2 | -1 | 6 | -22 | -23 |
| Tax % | 8% | -2% | -4% | -22% | 581% | -99% | -30% | -4% | 47% | 147% | 7% | -35% | -6% |
| Net Profit | -12 | -7 | -5 | -15 | -5 | -0 | -1 | -15 | -3 | -3 | 5 | -14 | -21 |
| EPS in Rs | -2.97 | -1.63 | -1.21 | -2.99 | -0.99 | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 |
Last Updated: August 20, 2025, 7:50 am
Below is a detailed analysis of the quarterly data for Lasa Supergenerics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 19.00 Cr..
- For Expenses, as of Jun 2025, the value is 21.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 15.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Jun 2025, the value is -2.00%. The value appears to be declining and may need further review. It has decreased from 9.00% (Mar 2025) to -2.00%, marking a decrease of 11.00%.
- For Other Income, as of Jun 2025, the value is -20.00 Cr.. The value appears strong and on an upward trend. It has increased from -22.00 Cr. (Mar 2025) to -20.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -23.00 Cr.. The value appears to be declining and may need further review. It has decreased from -22.00 Cr. (Mar 2025) to -23.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is -6.00%. The value appears to be increasing, which may not be favorable. It has increased from -35.00% (Mar 2025) to -6.00%, marking an increase of 29.00%.
- For Net Profit, as of Jun 2025, the value is -21.00 Cr.. The value appears to be declining and may need further review. It has decreased from -14.00 Cr. (Mar 2025) to -21.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -4.22. The value appears to be declining and may need further review. It has decreased from -2.85 (Mar 2025) to -4.22, marking a decrease of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:57 am
| Metric | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 132 |
| Expenses | -0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 128 |
| Operating Profit | -0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | 4 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | 3% | |
| Other Income | -0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -31 |
| Interest | -0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 2 |
| Depreciation | -0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 11 |
| Profit before tax | -0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -40 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| Net Profit | -0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -33 |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -6.61 | ||
| Dividend Payout % | -0% | -0% | -0% | -0% | 4% | -24% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -200.00% | 133.33% | 475.00% | -121.74% | -680.00% | 43.59% | 31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -700.00% | 333.33% | 341.67% | -596.74% | -558.26% | 723.59% | -11.77% |
Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | 1% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -28% |
| TTM: | 133% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -38% |
| 1 Year: | -73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 9:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:33 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 6 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 7 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 8 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 58 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 13 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
Below is a detailed analysis of the balance sheet data for Lasa Supergenerics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 50.00 Cr..
- For Reserves, as of Sep 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 34.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 2.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing). It has decreased from 16.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 72.00 Cr.. The value appears to be improving (decreasing). It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 20.00 Cr..
- For Total Assets, as of Sep 2025, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 30.00 Cr..
However, the Borrowings (7.00 Cr.) are higher than the Reserves (6.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -70.00 | -66.00 | -74.00 | -18.00 | 28.00 | -4.00 | -28.00 | -20.00 | 4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Diluted EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Cash EPS (Rs.) | -0.49 | -2.21 | -5.03 | 2.12 | 9.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.25 | 0.25 |
| Revenue From Operations / Share (Rs.) | 28.43 | 20.82 | 25.86 | 33.71 | 49.76 |
| PBDIT / Share (Rs.) | 2.25 | 0.45 | -0.95 | 3.86 | 11.62 |
| PBIT / Share (Rs.) | -0.20 | -1.68 | -3.63 | 0.41 | 7.73 |
| PBT / Share (Rs.) | -3.87 | -3.81 | -8.44 | -1.53 | 7.25 |
| Net Profit / Share (Rs.) | -2.94 | -4.34 | -7.71 | -1.32 | 5.60 |
| PBDIT Margin (%) | 7.91 | 2.17 | -3.69 | 11.44 | 23.36 |
| PBIT Margin (%) | -0.71 | -8.05 | -14.05 | 1.23 | 15.54 |
| PBT Margin (%) | -13.60 | -18.31 | -32.62 | -4.52 | 14.57 |
| Net Profit Margin (%) | -10.35 | -20.82 | -29.80 | -3.91 | 11.25 |
| Return on Networth / Equity (%) | -17.62 | -22.47 | -32.65 | -3.61 | 14.33 |
| Return on Capital Employeed (%) | -1.21 | -8.24 | -15.03 | 1.08 | 18.79 |
| Return On Assets (%) | -14.53 | -14.40 | -23.57 | -2.69 | 10.95 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 1.13 | 0.66 | 0.71 | 0.67 | 0.92 |
| Current Ratio (X) | 1.90 | 0.77 | 0.91 | 1.65 | 1.59 |
| Quick Ratio (X) | 0.46 | 0.38 | 0.59 | 1.39 | 1.16 |
| Inventory Turnover Ratio (X) | 4.97 | 4.81 | 8.67 | 6.13 | 4.69 |
| Interest Coverage Ratio (X) | 4.19 | 1.17 | -1.15 | 389.33 | 24.08 |
| Interest Coverage Ratio (Post Tax) (X) | 1.34 | -5.71 | -3.50 | 62.86 | 12.60 |
| Enterprise Value (Cr.) | 86.20 | 108.58 | 90.15 | 152.41 | 239.23 |
| EV / Net Operating Revenue (X) | 0.60 | 1.04 | 0.69 | 1.11 | 1.18 |
| EV / EBITDA (X) | 7.64 | 47.93 | -18.82 | 9.71 | 5.06 |
| MarketCap / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| Price / BV (X) | 1.01 | 1.14 | 0.78 | 1.14 | 1.53 |
| Price / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| EarningsYield | -0.17 | -0.19 | -0.41 | -0.03 | 0.09 |
After reviewing the key financial ratios for Lasa Supergenerics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.49. This value is below the healthy minimum of 3. It has increased from -2.21 (Mar 24) to -0.49, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.43. It has increased from 20.82 (Mar 24) to 28.43, marking an increase of 7.61.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 2.25, marking an increase of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.20. This value is below the healthy minimum of 0. It has increased from -1.68 (Mar 24) to -0.20, marking an increase of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.87. This value is below the healthy minimum of 0. It has decreased from -3.81 (Mar 24) to -3.87, marking a decrease of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 2. It has increased from -4.34 (Mar 24) to -2.94, marking an increase of 1.40.
- For PBDIT Margin (%), as of Mar 25, the value is 7.91. This value is below the healthy minimum of 10. It has increased from 2.17 (Mar 24) to 7.91, marking an increase of 5.74.
- For PBIT Margin (%), as of Mar 25, the value is -0.71. This value is below the healthy minimum of 10. It has increased from -8.05 (Mar 24) to -0.71, marking an increase of 7.34.
- For PBT Margin (%), as of Mar 25, the value is -13.60. This value is below the healthy minimum of 10. It has increased from -18.31 (Mar 24) to -13.60, marking an increase of 4.71.
- For Net Profit Margin (%), as of Mar 25, the value is -10.35. This value is below the healthy minimum of 5. It has increased from -20.82 (Mar 24) to -10.35, marking an increase of 10.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is -17.62. This value is below the healthy minimum of 15. It has increased from -22.47 (Mar 24) to -17.62, marking an increase of 4.85.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.21. This value is below the healthy minimum of 10. It has increased from -8.24 (Mar 24) to -1.21, marking an increase of 7.03.
- For Return On Assets (%), as of Mar 25, the value is -14.53. This value is below the healthy minimum of 5. It has decreased from -14.40 (Mar 24) to -14.53, marking a decrease of 0.13.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.13. It has increased from 0.66 (Mar 24) to 1.13, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has increased from 0.77 (Mar 24) to 1.90, marking an increase of 1.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 24) to 0.46, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.97. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 4.97, marking an increase of 0.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.19. This value is within the healthy range. It has increased from 1.17 (Mar 24) to 4.19, marking an increase of 3.02.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 3. It has increased from -5.71 (Mar 24) to 1.34, marking an increase of 7.05.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.20. It has decreased from 108.58 (Mar 24) to 86.20, marking a decrease of 22.38.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.60, marking a decrease of 0.44.
- For EV / EBITDA (X), as of Mar 25, the value is 7.64. This value is within the healthy range. It has decreased from 47.93 (Mar 24) to 7.64, marking a decrease of 40.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For Price / BV (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.14 (Mar 24) to 1.01, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For EarningsYield, as of Mar 25, the value is -0.17. This value is below the healthy minimum of 5. It has increased from -0.19 (Mar 24) to -0.17, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lasa Supergenerics Ltd:
- Net Profit Margin: -10.35%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.21% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -17.62% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.34
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 103 (Industry average Stock P/E: 62.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.35%
About the Company - Lasa Supergenerics Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722 | investor@lasalabs.com http://www.lasalabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Omkar Pravin Herlekar | Chairman & Managing Director |
| Mr. Shivanand G Hegde | Whole Time Director |
| Mr. Ajay Hareshlal Sukhwani | Independent Director |
| Ms. Manali Roop Bhagtani | Independent Director |
| Ms. Ekta Avtar Gurnasinghani | Independent Director |
| Mr. Hardesh Raja Tolani | Independent Director |
Lasa Supergenerics Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹23.51 |
| Previous Day | ₹23.66 |
FAQ
What is the intrinsic value of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd's intrinsic value (as of 04 December 2025) is 9.51 which is 4.33% lower the current market price of 9.94, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 49.4 Cr. market cap, FY2025-2026 high/low of 31.4/8.16, reserves of ₹6 Cr, and liabilities of 72 Cr.
What is the Market Cap of Lasa Supergenerics Ltd?
The Market Cap of Lasa Supergenerics Ltd is 49.4 Cr..
What is the current Stock Price of Lasa Supergenerics Ltd as on 04 December 2025?
The current stock price of Lasa Supergenerics Ltd as on 04 December 2025 is 9.94.
What is the High / Low of Lasa Supergenerics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lasa Supergenerics Ltd stocks is 31.4/8.16.
What is the Stock P/E of Lasa Supergenerics Ltd?
The Stock P/E of Lasa Supergenerics Ltd is 103.
What is the Book Value of Lasa Supergenerics Ltd?
The Book Value of Lasa Supergenerics Ltd is 11.2.
What is the Dividend Yield of Lasa Supergenerics Ltd?
The Dividend Yield of Lasa Supergenerics Ltd is 0.00 %.
What is the ROCE of Lasa Supergenerics Ltd?
The ROCE of Lasa Supergenerics Ltd is 1.00 %.
What is the ROE of Lasa Supergenerics Ltd?
The ROE of Lasa Supergenerics Ltd is 1.01 %.
What is the Face Value of Lasa Supergenerics Ltd?
The Face Value of Lasa Supergenerics Ltd is 10.0.